Home / Peptides / GHK-Cu: What the Research Shows and Where It Stands
GHK-Cu: What the Research Shows and Where It Stands
GHK-Cu is not an FDA-approved drug. What human and animal studies show, how FDA treats injectable vs non-injectable forms, and what hasn't been tested.
On this page
Quick facts
Fact sheet
- U.S. status
- Strongest evidence
- Limited human data
- Status verified
A copper-binding peptide found in cosmetic creams and serums, with little published human research. The regulatory status depends on the form. Here is what is known, form by form.
Key takeaways
- GHK-Cu is not an FDA-approved drug.
- The one controlled skin trial we could read found no objective improvement. Participants did report higher satisfaction.
- For wound healing, two older randomized trials of topical products point in different directions. We found no controlled human trial for scalp hair or recovery. The animal work we reviewed is not about skin.
- The regulatory status depends on the form. Non-injectable compounded GHK-Cu is on an FDA list of substances under evaluation; FDA flags immune-reaction risks and limited human data for injectable forms.
- GHK-Cu is not part of HHS’s Oct. 30, 2026 interim compounding policy. FDA says it intends to consult its advisory committee about GHK-Cu before the end of February 2027.
What is GHK-Cu?
GHK-Cu is a small peptide that binds copper. It shows up in three different settings, which people often blur together: cosmetic creams and serums, pharmacy-compounded products, and injectable products. They have different rules and different evidence. We have not reviewed cosmetic rules specific to GHK-Cu, so we make no claim about them here.
Is GHK-Cu FDA-approved?
No. It is not an approved drug. Its status in compounding depends on the route, and it is easy to misread. Dated Oct. 31, 2026:
| Form | Status | Source |
|---|---|---|
| Non-injectable, compounded | On FDA’s 503A Category 1 list (substances under evaluation for compounding). It was removed April 22, 2026, after nominations were withdrawn, and restored when a nominator clarified that it meant to withdraw only the injectable route | FDA list, May 14, 2026 |
| Injectable, compounded | Not in Category 1. The nomination was withdrawn. FDA cites a risk of immune reactions and “limited data in humans” | FDA |
| FDA advisory committee | FDA says it intends to consult its compounding advisory committee before the end of February 2027 | FDA list |
| HHS interim policy of Oct. 30, 2026 | GHK-Cu is not included | HHS policy, Appendix A |
| 503B outsourcing facilities | Not listed in FDA’s 503B nominations document, updated March 21, 2025. We did not find a later version | FDA 503B list |
Category 1 is not FDA approval, and it is not a statement that GHK-Cu is safe or effective. It means FDA is evaluating the substance. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness or quality before they are marketed.
State rules are separate. In 2026, boards in Alabama and Mississippi told licensees they may not compound, administer or dispense non-FDA-approved or research-grade peptides. The notices do not name GHK-Cu or mention cosmetics. We found no update from them as of Oct. 31, we did not review other states, and it isn’t clear how those notices apply to a given GHK-Cu product.
What does the human research show?
Very little. The only randomized controlled trial of GHK-Cu on skin that we found and could read:
| Study | Design | Participants | Result |
|---|---|---|---|
| Miller 2006 | Randomized, skin-care products after CO2 laser resurfacing | 13 completed | No objective difference in redness, wrinkles or skin quality. Greater self-reported satisfaction (p=0.04) |
Context for that result:
- It is small. Thirteen people cannot rule out a modest effect, and it tested a post-laser setting, not everyday aging.
- We could not rule out other studies. Our PubMed search found no other controlled skin trial of GHK-Cu with readable results. A 2026 systematic review reports that GHK-Cu reduced wrinkle volume and depth compared with controls; its abstract does not name that study, and it notes few well-designed trials. Industry-sponsored studies that are not indexed could exist.
- Satisfaction is not an objective result. In a small study, a participant’s own impression can reflect expectation as much as skin change.
- Reviews. A 2025 review of topical GHK reports “a surprising absence of clinical studies” of GHK-Cu and a related form in anti-wrinkle products. It still calls them effective, based on cell studies. A 2026 scoping review of six peptides, including GHK-Cu, concluded that their claimed benefits remain unsubstantiated by current human trials. That review is about recovery and performance, not skin.
For how GHK-Cu compares with collagen supplements and single-ingredient peptide creams for skin, see our guide to skin and aging.
What about hair, wound healing and recovery?
- Hair: we found no controlled trial of GHK-Cu for scalp hair growth. A 2026 review describes a randomized, vehicle-controlled eyebrow study in 18 healthy people that reported better hair count and diameter; we read only the review’s description, and the review calls the clinical evidence sparse. A placebo-controlled trial in 45 men tested a different product, a complex of GHK and 5-aminolevulinic acid.
- Wound healing: in diabetic foot ulcers (1994), a GHK-Cu gel closed plantar ulcers more than the inactive gel (median closure 98.5% vs 60.8%). In venous leg ulcers (1992, 86 evaluable patients), a tripeptide copper cream was no better than placebo; that abstract does not name GHK-Cu. We read the abstracts only, and neither result makes it an approved treatment.
- Recovery: the animal study we reviewed, a rat model of ACL reconstruction (72 animals), found a transient improvement. It does not show a benefit in people.
What about lab results showing it affects collagen?
GHK has been reported to affect collagen production in cells. That is a hypothesis about how it might work, not evidence of younger-looking skin or healed tissue. We found no clinical effect demonstrated by it.
What are the risks?
- Injectable GHK-Cu: FDA flags a risk of immune reactions from aggregation and impurities, and limited human data.
- Topical GHK-Cu: we did not find systematic long-term safety data in our review.
- Compounded products in general: not FDA-approved. Category 1 is not a guarantee of safety.
Which claims are not supported?
- “Clinically proven to erase wrinkles.” The one controlled skin trial we read found no objective improvement.
- “It regrows hair.” We found no controlled trial on scalp hair.
- “Injectable is stronger.” We found no basis for this, and FDA flags risks.
- “Category 1 means FDA-approved.” It does not.
- “It’s covered by the new HHS policy.” It is not named in it.
What should you ask a clinician or dermatologist?
- What does the evidence say about the skin or hair concern I have, and which options are FDA-approved for it?
- If a product contains GHK-Cu, is it a cosmetic or a compounded drug? Who makes it?
- Is an injectable form being proposed? If so, what are the immune-reaction risks and what is the evidence for my concern?
- How would we judge whether it is working?
We do not give doses or preparation instructions, and we do not recommend brands or sellers.
Frequently asked questions
Does GHK-Cu work for wrinkles?
The only randomized skin trial we could read found no objective improvement in wrinkles or redness after laser resurfacing, only higher self-reported satisfaction. It was small (13 people).
Is GHK-Cu FDA-approved?
No. It is not an approved drug.
Is injectable GHK-Cu safe?
FDA has flagged a risk of immune reactions and limited human data. Safety has not been established.
Is GHK-Cu legal?
We can’t answer that for every product or state. Non-injectable compounded forms are on FDA’s Category 1 list of substances under evaluation, which is not approval. FDA has flagged injectable forms. GHK-Cu is not named in HHS’s Oct. 30, 2026 interim policy. Boards in Alabama and Mississippi have issued notices on non-FDA-approved peptides, and we did not review cosmetic rules specific to GHK-Cu.
Does GHK-Cu grow hair?
We found no controlled trial on scalp hair. One small eyebrow study reported better results, and we read only a review’s description of it.
Sources we checked
- Miller 2006: GHK-Cu skin care after CO2 laser resurfacing (PubMed)PubMed. Accessed .
- Review of topical GHK, BioImpacts 2025 (PubMed)PubMed. Accessed .
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine, Am J Sports Med 2026 (PubMed)PubMed. Accessed .
- GHK-Cu in a rat ACL reconstruction model (PubMed)PubMed. Accessed .
- FDA 503A Category 1 list (updated May 14, 2026)FDA. Accessed .
- FDA: bulk drug substances that may present significant safety risksFDA. Accessed .
- FDA 503B list of bulk drug substancesFDA. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- Mulder 1994: GHK-Cu gel in diabetic foot ulcers (PubMed)PubMed. Accessed .
- Bishop 1992: copper tripeptide cream in venous leg ulcers (PubMed)PubMed. Accessed .
- Lee 2016: GHK and 5-aminolevulinic acid complex in hair loss (PubMed)PubMed. Accessed .
- Pharmaceutics 2026: review of GHK-Cu, eyebrow study (PubMed)PubMed. Accessed .
- GHK-Cu in aesthetic medicine, systematic review, Aesthet Surg J 2026 (PubMed)PubMed. Accessed .
- Alabama Board of Medical Examiners: notice on prescribing non-FDA-approved research-grade peptidesOther. Accessed .
- Mississippi nursing, pharmacy and medical licensure boards: joint statement on peptides (Aug. 19, 2026)Other. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.